Arcellx, Kite aim to keep chipping away at Carvykti advantage with new multiple myeloma data: #ASH23

Max Gelman

Senior Editor

SAN DIEGO — Arcellx raised the curtain on the CAR-T data it will present on Monday at the American Society of Hematology conference as it readies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Arcellx, Kite aim to keep chipping away at Carvykti advantage with new multiple myeloma data: #ASH23

Max Gelman

Senior Editor

Sign up to read this article for free.

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Vertex makes money from sickle cell therapy Casgevy

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Ar­cel­lx, Kite aim to keep chip­ping away at Carvyk­ti ad­van­tage with new mul­ti­ple myelo­ma da­ta: #ASH23

Max Gelman

Senior Editor

Sign up to read this article for free.

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe­si­ty

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Arcellx, Kite aim to keep chipping away at Carvykti advantage with new multiple myeloma data: #ASH23

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Vertex makes money from sickle cell therapy Casgevy

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks